Hepatitis C - Drug Pipeline Analysis and Market Forecasts to 2016

Summary

GlobalData has released a pharmaceutical and healthcare report, “Hepatitis C – Drug Pipeline Analysis and Market Forecasts to 2016”. The report is an essential source of information and analysis on the global hepatitis C market. The report identifies the key trends shaping and driving the global hepatitis C market. The report also provides insight into the prevalent competitive landscape and the emerging players expected to cause significant shifts in the positioning of the existing market leaders. Most importantly, the report provides valuable insight into the pipeline products within the global hepatitis C sector.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GlobalData’s team of industry experts.

GlobalData forecasts the global hepatitis C market to grow at 9.8% annually for the next seven years to reach $8.5 billion by 2016. This growth is primarily attributed to high unmet need in the market which is expected to be served by strong pipeline candidates. The growth will be further supported by the prevalence of the disease. GlobalData has concluded that the global hepatitis C market is underserved by the current product options and so there is significant scope for new entrants to capture value from underserved segments. Designing products with curative properties, high safety profiles and better patient compliance is one of key challenges for this market and could provide a significant market share for any company.

Scope

The scope of the report includes:

• Annualized global hepatitis C market revenues data from 2000 to 2009, forecast for seven years to 2016.
• Key geographies covered in this report include the United States (US), the United Kingdom (UK), Italy, Spain, Germany, France and Japan.
• Pipeline analysis data providing a split across different phases, mechanisms of action being developed and emerging trends. The key classes of mechanism of action include protease inhibitors, polymerase inhibitors, toll receptor agonists, drugs with interferon-like actions, HCV inhibitors and immunomodulators.
• Analysis of the current and future market competition in the global hepatitis C market. The key market players covered are Merck, Human Genome Sciences, Novartis, Vertex, Janssen, Mitsubishi, Tibotec and Roche.
• Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
• Key topics covered include a strategic competitor assessment, market characterization, unmet needs and implications for the future hepatitis C market.

Reasons to buy

The report will enhance your decision making capability in a more rapid and time sensitive manner. It will allow you to:

• Develop and design your in-licensing and out-licensing strategies through review of pipeline products and technologies and by identifying companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the global hepatitis C market.
• Drive revenues by understanding key trends, innovative products and technologies, market segments and companies likely to impact the global hepatitis C market in future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
• What’s the next big thing in the global hepatitis C market landscape? – Identify, understand and capitalize.

1 Table of Contents
    1.1 List of Tables
    1.2 List of Figures

2 Hepatitis C: Market Characterization
    2.1 Overview
    2.2 Hepatitis C Market Size
    2.3 Hepatitis C Market Forecast and Compound Annual Growth Rate
    2.4 Drivers and Barriers for Hepatitis C Market

        2.4.1 Drivers
        2.4.2 Restraints

    2.5 Opportunity and Unmet Need
    2.6 Key Takeaway

3 Hepatitis C Market : Competitive Assessment
    3.1 Overview
    3.2 Strategic Competitor Assessment

        3.2.1 PegIntron (Peginterferon alfa-2b) in combination with Rebetol (Ribavirin)
        3.2.2 Pegasys (peginterferon alfa-2a) in combination with Copegus (Ribavirin)
        3.2.3 Infergen (Interferon alfacon-1)
        3.2.4 Intron A (Interferon alfa 2b) in combination with Rebetol (Ribavirin)

    3.3 Key Takeaway

4 Hepatitis C Market: Pipeline Assessment
    4.1 Overview
    4.2 Strategic Pipeline Assessment

        4.2.1 Technology Trends Analytical Framework

    4.3 Hepatitis C - Promising Drugs under Clinical Development
    4.4 Drugs under Clinical Development

        4.4.1 Boceprevir (SCH 503034)
        4.4.2 Zalbin (albinterferon alfa-2b)
        4.4.3 Telaprevir ( VX 905)
        4.4.4 RG 7128

    4.5 Hepatitis C Market - Clinical Pipeline by Mechanism of Action
    4.6 Hepatitis C Pipeline - Pipeline by Clinical Phases of Development

        4.6.1 Hepatitis C Market - Phase III Clinical Pipeline
        4.6.2 Hepatitis C Market - Phase II Clinical Pipeline
        4.6.3 Hepatitis C Market - Phase I Clinical Pipeline
        4.6.4 Hepatitis C Market - Preclinical Pipeline
        4.6.5 Hepatitis C Market - Discovery

    4.7 Discontinued / Suspended Drugs for Hepatitis C
    4.8 Key Takeaway

5 Hepatitis C Market: Implications for Future Market Competition

6 Hepatitis C Market: Future Players in the Hepatitis C Market
    6.1 Introduction

        6.1.1 Merck & Co
        6.1.2 F. Hoffmann-La Roche and Pharmasset
        6.1.3 Human Genome Sciences and Novartis
        6.1.4 Vertex Pharmaceuticals and Tibotec Pharmaceuticals

7 Hepatitis C Market: Appendix
    7.1 Definitions
    7.2 Abbreviations
    7.3 Research Methodology

        7.3.1 Coverage
        7.3.2 Secondary Research
        7.3.3 Forecasting
        7.3.4 Primary Research
        7.3.5 Expert Panels

    7.4 Contact Us
    7.5 Disclaimer
    7.6 Sources

1.1 List of Tables
    Table 1: Global Hepatitis C Market, Revenues ($m), 2001-2009
    Table 2: Global Hepatitis C Market, Revenues ($m), 2009-2016
    Table 3: Major Marketed Products in the Hepatitis C Market, 2010
    Table 4: Hepatitis C - Most Promising Drugs Under Clinical Development, 2010
    Table 5: Final Prove 3 SVR Results for telaprevir, Hepatitis C
    Table 6: Study Design for Phase II b study for RG7128, Hepatitis C
    Table 7: Hepatitis C Market - Phase III Clinical Pipeline, 2010
    Table 8: Hepatitis C Market - Phase II Clinical Pipeline, 2010
    Table 9: Hepatitis C Market - Phase I Clinical Pipeline, 2010
    Table 10: Hepatitis C Market - Pre Clinical Pipeline, 2010
    Table 11: Hepatitis C Market - Discovery, 2010
    Table 12: Discontinued/Suspended Drugs for Hepatitis C, 2010
    Table 13: Merck & Co. - Hepatitis C marketed products, 2010
    Table 14: Merck & Co. - Hepatitis C pipeline products, 2010
    Table 15: Study Design for Phase II for RG7128, Hepatitis C
    Table 16: Hoffmann-La Roche - Hepatitis C marketed products, 2010
    Table 17: Hoffmann-La Roche - Hepatitis C pipeline product, 2010
    Table 18: Pharmasset - Hepatitis C marketed products, 2010
    Table 19: Human Genome Sciences - Hepatitis C pipeline products, 2010
    Table 20: Novartis - Hepatitis C pipeline products, 2010
    Table 21: Final Prove 3 SVR Results for telaprevir-based, Hepatitis C
    Table 22: Vertex - Hepatitis C pipeline products, 2010
    Table 23: Tibotec Pharmaceuticals - Hepatitis C pipeline products, 2010

1.2 List of Figures
    Figure 1: Hepatitis C Market, Global, Revenues ($m), 2001-2009
    Figure 2: Hepatitis C Market, Global, Revenues ($m), 2009-2016
    Figure 3: Opportunity and Unmet Need in the hepatitis C Market, 2016
    Figure 4: Strategic Competitive Assessment of major marketed products in Hepatitis C market, 2010
    Figure 5: Technology Trends Analytic Framework of the Hepatitis C Pipeline, 2010
    Figure 6: Technology Trends Analytic Framework of Hepatitis C, Description, 2010
    Figure 7: Hepatitis C Market - Clinical Pipeline by Mechanism of Action, 2010
    Figure 8: Hepatitis C Pipeline by Phase of Clinical Development, 2010
    Figure 9: Implications for Future Market Competition in the Hepatitis C Market, 2010
    Figure 10: Hepatitis C Market - Clinical Pipeline by Company, 2010
    Figure 11: GlobalData Methodology, 2010
    Figure 12: GlobalData Market Forecasting Model, 2010